p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma

Cancer

Volumn 83, Issue 1, 1998, Pages 7-18

  Ribeiro Jr , Ulysses ^a   Finkelstein, Sydney D ^a   Safatle Ribeiro, Adrians V ^a   Landreneau, Rodney J ^a   Clarke, Martha R ^a   Bakker, Anke ^a   Swalsky, Patricia A ^a   Gooding, William E ^a   Posner, Mitchell C ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Esophageal tumors; Genotyping; P53; Prognosis; Radiotherapy

Indexed keywords

ALPHA INTERFERON; CISPLATIN; FLUOROURACIL; PROTEIN P53;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; POINT MUTATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, P53; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POINT MUTATION; PROGNOSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 2642655267     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980701)83:1<7::AID-CNCR2>3.0.CO;2-R     Document Type: Article

References (68)

1. Parkin DM, Laara E, Muir CS. Estimates of the world-wide frequency of sixteen major cancers in 1980. Int J Cancer 1988;41:184-97.
2. Powell I, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 1990;62:440-3.
3. Blot WJ, Devesa SS, Fraumeni JF. Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA 1993;270: 1320.
4. Ribeiro U Jr., Posner MC, Safatle-Ribeiro AV, Reynolds JC. Risk factors for squamous cell carcinoma of the oesophagus. Br J Surg 1996;83:1174-85.
5. American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society, 1988.
6. Fearon ER, Volgelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
7. Finlay CA, Hinds PW, Levine AJ. The p53 protooncogene can act as a suppressor of transformation. Cell 1989;57:1083-93.
8. Hollstein MC, Sidranski D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
9. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990;87:9958-61.
10. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 1991;51:4495-9.
11. Tamura G, Maesawa C, Suzuki Y, Satodate R, Ishida K, Saito K. p53 gene mutations in esophageal cancer detected by polymerase chain reaction single-strand conformation polymorphism analysis. Jpn J Cancer Res 1992;83:559-62.
12. Sasano H, Miyazaki S, Gooukon Y, Nishihira T, Sawai T, Nagura H. Expression of p53 in human esophageal carcinoma: an immunohistochemical study with correlation to proliferating cell nuclear antigen expression. Hum Pathol 1992;23:1238-43.
13. Furihata M, Ohtsuki Y, Ogoshi S, Takahashi A, Tamiya T, Ogata T. Prognostic significance of human papillomavirus genomes (type-16, -18) and aberrant expression of p53 protein in human esophageal cancer. Int J Cancer 1993;54:226-30.
14. Goukon Y, Sasano H, Nishihira T, Nagura H, Mori S. p53 overexpression in human esophageal carcinoma: a correlation with DNA ploidy and two parameter flow cytometric study. Anticancer Res 1994;14:1305-12.
15. Fléjou J-F, Paraf F, Potet F, Muzeau F, Fékété F, Hénin D. p53 protein expression in Barrett's adenocarcinoma: a frequent event with no prognostic significance. Histopathology 1994;24:487-9.
16. Hamelin R, Fléjou JF, Muzeau F, Potet F, Laurent-Puig P, Fékété F, et al. Tp53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994;107:1012-8.
17. Sauter ER, Keller SM, Erner SM. p53 correlates with improved survival in patients with esophageal adenocarcinoma. J Surg Oncol 1995;58:269-73.
18. Wang DY, Xiang YY, Tanaka M, Li XR, Li JL, Shen Q, et al. High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China and its relationship to progression and prognosis. Cancer 1994;74:3089-96.
19. Vijeyasingam R, Darnton SJ, Jenner K, Allen CA, Billingham C, Mattheus HR. Expression of p53 protein in oesophageal carcinoma: clinicopathological correlation and prognostic significance. Br J Surg 1994;81:1623-6.
20. Duhaylongsod FG, Gottfried MR, Iglehart JD, Vaughn AL, Wolfe WG. The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg 1995;221:677-84.
21. Casson AG, Kerkvliet N, O'Malley F. Prognostic value of p53 protein in esophageal adenocarcinoma. J Surg Oncol 1995; 60:5-11.
22. Chanvitan A, Nekarda H, Casson AG. Prognostic value of DNA index, s-phase fraction and p53 protein accumulation after surgical resection of esophageal squamous-cell carcinomas in Thailand. Int J Cancer 1995;63:381-6.
23. Bennett WP, Hollstein MC, Metcalf RA, Welsh JA, He A, Zhu S, et al. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 1992;52:6092-7.
24. Symmans PJ, Linehan JM, Brito MJ, Filipe MI. p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7. J Pathol 1994;173:221-6.
25. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
26. Lane DP. p53, guardian of the genome. Nature 1992;358: 15-6.
27. Oren M. Relationship of p53 to the control of apoptotic cell death. Semin Cancer Biol 1994;5:221-7.
28. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hosteller R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989;342:705-8.
29. Beahrs OH, Henson DE, Hutler RVP, Kennedy BJ, editors. American Joint Committee on Cancer. Manual for staging of cancer. Philadelphia: J.B. Lippincott Company, 1992.
30. Hsu SM, Raine L, Fanger H. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
31. Shi SR, Key ME, Kalra K. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39: 741-8.
32. Finkelstein SD, Sayegh R, Bakker A, Swalsky PA. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 1993;128:526-32.
33. Pricolo VE, Finkelstein SD, Wu T, Keller G, Bakker A, Swalsky PA, et al. Prognostic value of Tp53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am J Surg 1996;171:41-6.
34. Ribeiro U Jr., Safatle-Ribeiro AV, Posner MC, Rosendale B, Bakker A, Swalsky PA, et al. Comparative p53 mutational analysis of multiple primary cancers of the upper aerodigestive tract. Surgery 1996;120:45-53.
35. Popp MB, Hawley D, Reising J, Bongiovanni G, Weesner R, Moomaw CJ, et al. Improved survival in squamous esophageal cancer. Preoperative chemotherapy and irradiation. Arch Surg 1986;121:1330-5.
36. Poplin E, Fleming T, Leichman L, Seydel HG, Steiger Z, Taylor S, et al. Combined therapies for squamous-cell carcinoma of the esophagus: a Southwest oncology group study (SWOG-8037). J Clin Oncol 1987;5:622-8.
37. Seydel HG, Leichman L, Byhardt R, Cooper J, Herskovic A, Libnock J, et al. Preoperative radiation and chemotherapy for localized squamous cell carcinoma of the esophagus: a RTOG study. Int J Radiat Oncol Biol Phys 1987;14:33-5.
38. MacFarlane SD, Hill LD, Jolly PC, Kozarek RA, Anderson RP. Improved results of surgical treatment for esophageal and gastroesophageal junction carcinomas after preoperative combined chemotherapy and radiation. J Thorac Cardiovasc Surg 1988;95:415-2.
39. Herskovic A, Leichman L, Lattin P, Han I, Ahmad K, Leichman CG, et al. Chemo/radiation with and without surgery in the thoracic esophagus: the Wayne state experience. Int J Radiat Oncol Biol Phys 1988;15:655-62.
40. Lackey VL, Reagan MT, Smith RA, Anderson WJ. Neoadjuvant therapy of squamous cell carcinoma of the esophagus: role of resection and benefit in partial responders. Ann Thorac Surg 1989;48:218-21.
41. Forastiere AA, Orringer MB, Perez-Tamayo C, Urba SG, Husted S, Takasugi BJ, et al. Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J Clin Oncol 1990;8:119-27.
42. Mercke C, Albertsson M, Hambraeus G, Tennvall J, Lillo-Gill R, Samuelsson L, et al. Cisplatin and 5-FU combined with radiotherapy and surgery in the treatment of squamous cell carcinoma of the esophagus. Palliative effects and tumor response. Acta Oncol 1991;30:617-22.
43. Kavanagh B, Anscher M, Leopold K, Deutsch M, Gaydica E, Dodge R, et al. Patterns of failure following combined modality therapy for esophageal cancer, 1984-1990. Int J Radiat Oncol Biol Phys 1992;24:633-42.
44. Kelsen D, Louett D, Wong J, Saltz L, Buckley M, Murray P, et al. Interferon alfa-2a and fluorouracil in treatment of patients with advanced esophageal cancer. J Clin Oncol 1992; 10:269-74.
45. Wolfe WG, Vaughn AL, Seigler HF, Hathorn JW, Leopold KA, Duhaylongsod FG. Survival of patients with carcinoma of the esophagus treated with combined-modality therapy. J Thorac Cardiovasc Surg 1993;105:749-59.
46. Stewart JR, Hoff SJ, Johnson DH, Murray MJ, Butler DR, Elkins CC, et al. Improved survival with neoadjuvant therapy and resection for adenocarcinoma of the esophagus. Ann Surg 1993;218:571-8.
47. Jung M, Notario V, Dritshcilo A. Mutations in the p53 gene in radiation-sensitive and resistant human squamous carcinoma cells. Cancer Res 1992;52:6390-3.
48. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 1993;53:3667-9.
49. Lowe SW, Schimitt EM, Smith SW, Osborne BA, Jacks T, et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-9.
50. Nabeya Y, Loganzo F Jr., Maslak P, Lai L, Oliveira AR, Schwartz GK, et al. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 1995;64: 37-46.
51. Remvikos Y, Lauren-Puig P, Salmon RJ, Frelat G, Dutril-Laux B, Thomas G. Simultaneous monitoring of p53 protein and DNA content of colorectal adenocarcinoma by flow cytometry. Int J Cancer 1990;45:450-6.
52. Lendinko N, Constantino RL. Modulation of p53-gene expression and cytokeratin 18 in retinoid-mediated invasion-suppressed lung carcinoma cells. Anticancer Res 1990; 10: 1335-9.
53. Trainer DL, Kline T, McCabe FL, Faucette LF, Field J, Chaikin M, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int J Cancer 1988;41:287-96.
54. Pohl J, Lehmann V, Radler-Pohl A, Schirrmacher V. Induction of the metastatic phenotype by transfection of the nuclear oncogene p53: increases in cytoplasmic diacylglycerol levels and reduction in class-I-MHC antigen expression are not sufficient to explain the changes in metastatic capacities. J Cancer Res Clin Oncol 1989;115:145-7.
55. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukotomi T, et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991; 82:835-40.
56. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992;50:859-62.
57. Dolcetti R, Doglioni C, Maestro R, Gasparotto D, Barzan L, Pastore A, et al. p53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: genetic and prognostic implications. Int J Cancer 1992;52:178-82.
58. Shimaya K, Shiozaki H, Inoue M, Tahara H, Monden T, Shimano T, et al. Significance of p53 expression as a prognostic factor in esophageal squamous cell carcinoma. Virchows Arch A Pathol Anat Histopathol 1993;422:271-6.
59. Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert HE. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994;74:2218-23.
60. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
61. Wynford-Thomas D. p53 in tumor pathology: can we trust immunocytochemistry? J Pathol 1992;166:329-30.
62. Hall PA, Lane DP. p53 in tumor pathology: can we trust immunohistochemistry? - revisited. J Pathol 1994;172:1-4.
63. Lu X, Lane DP. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 1993;75:765-78.
64. Lane D. p53 and human cancers. Br Med Bull 1994;50:582-99.
65. Przygodzski RM, Finkelstein SD, Langer JC, Swalsky PA, Fishback N, Bakker A, et al. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 1996, 148:1531-41.
66. Coggi G, Bosari S, Roncelli M, Graziani D, Bossi P, Viale G, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 1997;79:425-32.
67. Gleeson CM, Sloan JM, McGuigan JA, Ritchie AJ, Russell SE. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res 1995; 55:3406-11.
68. Muzeau F, Fléjou JF, Potet F, Belghiti J, Thomas G, Hamelin R. Profile of p53 mutations and abnormal expression of p53 protein in 2 forms of esophageal cancer. Gastroenterol Clin Biol 1996;20:430-7.